Ioa Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

ioa

n.v. organon - nomegestrol acetat, estradiol - prevensjon - sex hormoner og modulatorer av genital systemet, - oral prevensjon.

Zoely Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

zoely

theramex ireland limited - nomegestrol acetat, estradiol - prevensjon - sex hormoner og modulatorer av genital systemet, - oral contraception,.

Qlaira - Νορβηγία - Νορβηγικά - Statens legemiddelverk

qlaira -

bayer ab - solna - Østradiolvalerat / dienogest - tablett, filmdrasjert

Yasmin 28 0.03 mg / 3 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

yasmin 28 0.03 mg / 3 mg

bayer ab - solna - etinyløstradiol / drospirenon - tablett, filmdrasjert - 0.03 mg / 3 mg

Yasminelle 28 0.02 mg / 3 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

yasminelle 28 0.02 mg / 3 mg

bayer ab - solna - etinyløstradiolbetadeksklatrat / drospirenon - tablett, filmdrasjert - 0.02 mg / 3 mg

Yasmin 0.03 mg / 3 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

yasmin 0.03 mg / 3 mg

bayer ab - solna - etinyløstradiol / drospirenon - tablett, filmdrasjert - 0.03 mg / 3 mg

Yasminelle 0.02 mg / 3 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

yasminelle 0.02 mg / 3 mg

bayer ab - solna - etinyløstradiolbetadeksklatrat / drospirenon - tablett, filmdrasjert - 0.02 mg / 3 mg

Yaz 0.02 mg / 3 mg Νορβηγία - Νορβηγικά - Statens legemiddelverk

yaz 0.02 mg / 3 mg

bayer ab - solna - etinyløstradiolbetadeksklatrat / drospirenon - tablett, filmdrasjert - 0.02 mg / 3 mg

Drovelis Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

drovelis

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - sex hormoner og modulatorer av genital systemet, - oral contraceptive.

Lydisilka Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

lydisilka

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - sex hormoner og modulatorer av genital systemet, - oral prevensjon. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.